Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer

25 Jul 2020

Abstract excerpt

The purpose of the current study is to investigate the prognostic significance of M2 isoform of pyruvate kinase (PKM2) mRNA expression loss in patients with operable colon cancer (CC). Two hundred sixty-two specimens from patients with stage-III or high-risk stage-II CC (group-A) treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy (FOLFOX), 118 specimens from metastatic CC patients (group-B)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Colorectal Cancer Treatments and Studies
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32722474
DOI: 10.3390/cancers12082058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal CancerPMID 32722474Read ↗

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell LinesSemantic proximity Read ↗

Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.Semantic proximity Read ↗

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cellsSemantic proximity Read ↗

The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro studySemantic proximity Read ↗

Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancerSemantic proximity Read ↗

Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell linesSemantic proximity Read ↗

Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent ChemotherapySemantic proximity Read ↗

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancerSemantic proximity Read ↗

Repression of cell cycle–related proteins by oxaliplatin but not cisplatin in human colon cancer cellsSemantic proximity Read ↗

Elevating PKM2 Expression Indicates a Biomarker of Poor Prognosis in Patients With Liver CancerSemantic proximity Read ↗

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancerSemantic proximity Read ↗

The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.